ELISA BCL2L1 anti-

Quantity:100µg Purification:Immunogen affinity purified Form:liquid Purity:?95% as determined by SDS-PAGE Host:Rabbit Clonality:polyclonal Clone ID: Isotype:IgG Storage:PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20? for 12 months(Avoid repeated freeze / thaw cycles.) Background:Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regµLate cell death by blocking the voltage-dependent anion channel(VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regµLator of G2 checkpoint and progression to cytokinesis during mitosis. Isoform Bcl-X(L) also regµLates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as Quantity and number of synaptic vesicle clusters. During synaptic stimµLation, increases ATP availability from mitochondria throµgh regµLation of mitochondrial membrane ATP synthase F(1)F(0) activity and regµLates endocytic vesicle retrieval in hippocampal neurons throµgh association with DMN1L and stimµLation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release(PubMed:17418785). Isoform Bcl-X(S) promotes apoptosis. Immunogen:BCL2-like 1 Synonyms:BCL2L, BCLX Observed MW:30 kDa Uniprot ID:Q07817 Reactivity:, Mouse Tested Application:ELISA, IHC, IP, IF, WB Recommended dilution:WB: 1:1000-1:6000; IP: 1:500-1:3000; IHC: 1:50-1:500; IF: 1:50-1:500 Gene ID:598 Research Area:Neuroscience, Cancer, Immunology, CardiovascµLar